Avacta Group and OncoSec Medical Incorporated have entered into a research collaboration to combine Avacta’s Affimer protein platform with OncoSec’s gene delivery technology ImmunoPulse. The research program will evaluate the benefits of delivering Affimer protein genes directly into tumors using the OncoSec technology with the long-term aim of developing gene delivered Affimer immunotherapies.   The collaboration between the companies aims to show that, by using ImmunoPulse to deliver D...